# Late Effects and Quality of Life after CAR T-cell Therapy

#### Hosted by BMT InfoNet

December 18th, 2024



P. Connor Johnson MD Massachusetts General Hospital

Many thanks to Bristol Myers Squibb whose support helped make this presentation possible.



#### Late Effects and Quality of Life after CAR T-cell Therapy

P. Connor Johnson, MD Assistant Professor of Medicine Massachusetts General Hospital Harvard Medical School







#### P. Connor Johnson, MD



Dr. Connor Johnson is an Assistant Professor of Medicine at Harvard Medical School and an attending oncologist at Massachusetts General Hospital. He specializes in cellular therapies such as CAR T-cell therapy and the treatment of patients with lymphoma.

Dr. Johnson's research focuses on addressing the supportive care needs and mitigating the therapy toxicity of patients with lymphoma and patients receiving cellular therapy.







• The basics of CAR-T cell Therapy

- The patient journey during CAR-T cell therapy
- Psychosocial experience of patients undergoing CAR-T cell therapy
- CAR-T Cell therapy: living with immense prognostic uncertainty
- Early recovery and long-term effects after CAR-T cell Therapy
- Survivorship and beyond





### **CAR-T Overview**



- Chimeric antigen receptor (CAR)-T cell therapy:
  - A form of immunotherapy that uses the cells of the immune system to treat cancer
- 6 FDA-approved products to treat lymphomas, leukemias, and multiple myeloma
- > 100 clinical trials in both solid and blood cancers





# **Chimeric antigen receptor (CAR)**



Genetically engineered antigenbinding domain (like a latch to bind cancer cells)

#### Normal T-cell








#### **CAR-T Overview**







Courtesy of Marcela Maus



# **CAR-T Overview**




- CAR-T cell therapy is currently approved to treat patients with relapsed/refractory blood cancers such as lymphoma, chronic lymphocytic leukemia and multiple myeloma
- Aggressive lymphomas: often eligible after 1 or 2 prior treatments
- Indolent lymphomas, leukemias, and multiple myeloma: usually eligible after multiple prior treatments





### **Patient Journey**





Б

#### **CAR-T Toxicities**



Symptoms of Cytokine Release Syndrome (CRS)		
Fever	Low oxygen	
Chills	Low blood pressure	
Muscle aches	Joint aches	
Fatigue	Headache	
Loss of appetite	Organ injury	





#### **CAR-T Toxicities**



Symptoms of Neurologic Toxicity		
Confusion	Somnolence	
Trouble with speech or language	Agitation	
Trouble with writing	Seizure	
Tremors	Brain swelling	





# **Other CAR-T Toxicities**



- Low blood counts
- Low immunoglobulin levels
- Infections
- Immune effector cell-associated hemophagocytic syndrome (IEC-HS) (rare)
- Second cancers (rare)
- Movement and neurocognitive treatment-emergent adverse events (MNTs)





#### **IEC-HS**



- Hyperinflammatory syndrome that typically occurs after cytokine release syndrome has resolved
- Not well understood, but immune cells (T-cells and macrophages) become overactivated
- Abnormalities in coagulation (ability of blood to clot), low blood counts, very elevated ferritin (lab test), and inflammation in the liver are common features
- Disease burden and CAR T-cell product are some risk factors
- Rare, occurring in 1-3% of patients
- Usually managed with anakinra (anti-inflammatory medication) and steroids



# Symptoms during CAR-T



Disease Symptoms	Moderate to Severe
Pain	42.9%
Difficulty swallowing	14.3%
Cough	9.5%
Shortness of breath	9.5%
Neuropathy	4.8%
Abdominal bloating	4.8%
Itching	4.8%
Light-headedness	4.8%



# Symptoms during CAR-T




CAR-T Symptoms	Moderate to Severe
Fatigue	61.9%
Lack of appetite	28.6%
Headache	28.6%
Chills	28.6%
Feeling confused	23.8%
Memory loss	14.3%
Pain	9.5%
Vomiting	9.5%
Light-headedness	9.5%
Diarrhea	9.5%





Whisenant, et al. Seminars in Oncology Nursing 2021

#### **Physical Symptoms During CAR-T**








MGH

1811

# **Psychological Symptoms Over Time**








MGH


1811

#### **Prognostic Uncertainty**



- Increase in prognostic uncertainty in oncology with novel therapies, especially CAR-T cell therapy
- How to focus on living well and acknowledge risks?









# **Early Recovery After CAR-T**



- Patients typically followed closely at CAR-T center until day 30-60
- Close monitoring for CRS and neurotoxicity during the first 30 days
- Often living away from home during first 30 days after CAR-T
- Residual physical and functional limitations early after treatment
- Fatigue common and persistent up to 6 months post-CAR-T
- Risk of infections after treatment (viral is biggest risk)






# **Quality of Life (QOL) During and After CAR-T**



- QOL measured over time (higher is better)
- On average improving by 3-6 months after CAR-T and similar to US population average
- No factors were associated with negative QOL trajectory






Johnson, et al. Blood Advances 2023.



# Early Recovery after CAR-T for Lymphoma








MGH 1811

# **Early Recovery after CAR-T for Lymphoma**



Time after liso-cel administration






MGH 1811

#### Quality of Life with CAR-T Compared to Chemotherapy in Lymphoma



**CAR-T in Blue** 

#### **CAR-T in Red**






Elsawy et al. Blood 2022. Abramson, et al. Blood 2022.














#### Survivorship after CAR-T











### **Survivorship Concerns**

1811



#### Long Term Quality of Life After CAR-T for Leukemia in Pediatrics and Young Adults







MGH 1811

# **Survivorship Concerns**



- Compared to the general population, CAR-T survivors at 1-5 years post-CAR-T were *not* different in:
  - Quality of life scores
  - Physical health
  - Mental health
- 37.5% reported cognitive difficulties






#### **Neurocognitive Outcomes 6 Months After CAR-T**



- No difference in average scores 6 months after CAR-T compared to baseline
- No response to CAR-T was associated with worse neurocognitive outcomes





#### Movement and Neurocognitive Treatment-Emergent Adverse Events (MNTs)

- Paralysis of cranial nerves or syndrome that resembles Parkinson's disease with tremors, trouble with movement, memory difficulties
- Occurs with CAR-T cell therapies, primarily targeting BCMA, which is used in multiple myeloma, most commonly with cilta-cel
- Poorly understood, but often occurs more than 4 weeks after infusion
- Risk factors appeared to be high tumor burden, higher grade CRS, presence of neurotoxicity, high levels of persistent CAR-T cells
- In one study occurred in 5% of cilta-cel patients
- Treatment is evolving, usually involves steroids or cyclophosphamide
- More aggressive bridging therapy strategies and CRS/neurotoxicity treatment may reduce the risk





### Second Cancers after CAR-T



- 25/724 patients developed second cancers after CAR-T with a median follow up of 15 months (3.4%)
  - 13 patients had myelodysplastic syndrome or acute leukemia (1.8%)
  - 1 patient had a T-cell lymphoma (0.1%)
  - 11 patients had solid tumor malignancies (1.5%)





# **Effect on Caregivers**




- Caregivers provide majority of care for CAR-T recipients
- Caregivers monitor for toxicities early in the recovery period
- Caregivers have a stressful job
- Chronic caregiving especially in the context of CAR-T
- Immense caregiving burden
- Impact on relationships
- Impact on caregiver health
- Financial burden is immense





#### **Effect on Caregivers**







Barata et al. Transplant Cell Ther. 2024.



# Conclusions



- Generally, quality of life and symptom burden improve over time after CAR-T across blood cancers
- Quality of life decreases by two weeks after CAR-T but improves on average by 3-6 months after CAR-T
- CAR-T survivors have quality of life similar to the general population
- Physical and psychological symptoms improve, though for a subset of patients can persist
- Cognitive outcomes long-term appear good based on research to date
- Caregivers of patients receiving CAR-T experience significant psychological symptoms





# **Questions?**



Sarah Meredith High Risk Myeloma CAR T May 2022





#### **P. Connor Johnson MD** Massachusetts General Hospital



Paul Gerhardt Follicular Lymphoma CAR T May 2021

Many thanks to Bristol Myers Squibb whose support helped make this presentation possible.

#### Let Us Know How We Can Help You!



Many thanks to Bristol Myers Squibb whose support helped make this presentation possible. Visit our website: bmtinfonet.org

Email us: help@bmtinfonet.org

Phone: 888-597-7674 or 847-433-3313

#### Find us on:



facebook.com/bmtinfonet



Instagram.com/bmtinfonet



twitter.com/BMTInfoNet

